Viatris Revenue 2010-2024 | VTRS

Viatris annual/quarterly revenue history and growth rate from 2010 to 2024. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
  • Viatris revenue for the quarter ending June 30, 2024 was $3.797B, a 3.11% decline year-over-year.
  • Viatris revenue for the twelve months ending June 30, 2024 was $15.239B, a 2.32% decline year-over-year.
  • Viatris annual revenue for 2023 was $15.427B, a 5.14% decline from 2022.
  • Viatris annual revenue for 2022 was $16.263B, a 9.08% decline from 2021.
  • Viatris annual revenue for 2021 was $17.886B, a 49.73% increase from 2020.
Viatris Annual Revenue
(Millions of US $)
2023 $15,427
2022 $16,263
2021 $17,886
2020 $11,946
2019 $11,501
2018 $11,434
2017 $11,908
2016 $11,077
2015 $9,429
2014 $7,720
2013 $6,909
2012 $6,796
2011 $6,130
2010 $5,451
2009 $5,093
Viatris Quarterly Revenue
(Millions of US $)
2024-06-30 $3,797
2024-03-31 $3,663
2023-12-31 $3,837
2023-09-30 $3,942
2023-06-30 $3,919
2023-03-31 $3,729
2022-12-31 $3,876
2022-09-30 $4,078
2022-06-30 $4,117
2022-03-31 $4,192
2021-12-31 $4,342
2021-09-30 $4,537
2021-06-30 $4,578
2021-03-31 $4,430
2020-12-31 $3,624
2020-09-30 $2,972
2020-06-30 $2,731
2020-03-31 $2,619
2019-12-31 $3,192
2019-09-30 $2,962
2019-06-30 $2,852
2019-03-31 $2,496
2018-12-31 $3,079
2018-09-30 $2,862
2018-06-30 $2,808
2018-03-31 $2,685
2017-12-31 $3,239
2017-09-30 $2,987
2017-06-30 $2,962
2017-03-31 $2,720
2016-12-31 $3,268
2016-09-30 $3,057
2016-06-30 $2,561
2016-03-31 $2,191
2015-12-31 $2,491
2015-09-30 $2,695
2015-06-30 $2,372
2015-03-31 $1,872
2014-12-31 $2,083
2014-09-30 $2,084
2014-06-30 $1,837
2014-03-31 $1,716
2013-12-31 $1,809
2013-09-30 $1,767
2013-06-30 $1,702
2013-03-31 $1,632
2012-12-31 $1,723
2012-09-30 $1,802
2012-06-30 $1,688
2012-03-31 $1,584
2011-12-31 $1,531
2011-09-30 $1,576
2011-06-30 $1,574
2011-03-31 $1,449
2010-12-31 $1,434
2010-09-30 $1,355
2010-06-30 $1,369
2010-03-31 $1,292
2009-12-31 $1,352
2009-09-30 $1,264
2009-06-30 $1,267
2009-03-31 $1,210
Sector Industry Market Cap Revenue
Medical Medical Services $13.858B $15.427B
Viatris, Inc. is a global healthcare company. Its portfolio comprises more than thousand approved molecules across a wide range of key therapeutic areas, including globally recognized iconic and key brands, generic, complex generic, and biosimilar products. Branded products include EpiPen, Amitiza, Lipitor and Viagra. Biosimilars portfolio include pegfilgrastim, trastuzumab and adalimumab biosimilars. It has obtained approval for the biosimilar of Avastin and Insulin Aspart in Europe. The company reports in following segments: Developed Markets, Greater China, JANZ & Emerging Markets. The Developed Markets segment comprises operations in N. America and Europe. The Greater China segment operates in China, Taiwan and Hong Kong. The JANZ segment will report for operations in Japan, Australia and New Zealand, while the Emerging Markets segment will include operations in Asia, the Middle East, South and Central America, Africa and E. Europe. This segment also includes the company's anti-retroviral franchise.
Stock Name Country Market Cap PE Ratio
Elevance Health (ELV) United States $96.890B 12.02
Cencora (COR) United States $46.107B 17.62
DiDi Global (DIDIY) China $23.233B 0.00
ICON (ICLR) Ireland $18.679B 16.64
Revvity (RVTY) United States $15.535B 26.63
Avantor (AVTR) United States $15.498B 23.24
Natera (NTRA) United States $15.385B 0.00
BioMerieux (BMXMF) France $13.601B 0.00
Solventum (SOLV) United States $12.636B 0.00
CochLear (CHEOY) Australia $12.565B 0.00
Medpace Holdings (MEDP) United States $10.202B 28.74
Charles River Laboratories (CRL) United States $9.742B 18.41
Sonic Healthcare (SKHHY) Australia $8.273B 0.00
HealthEquity (HQY) United States $7.792B 42.29
Doximity (DOCS) United States $7.787B 49.34
Bausch + Lomb (BLCO) Canada $6.975B 32.47
Life Times (LTH) United States $4.762B 31.52
PACS (PACS) United States $4.502B 0.00
Sotera Health (SHC) United States $4.367B 23.36
Organon (OGN) United States $4.239B 4.28
Surgery Partners (SGRY) United States $3.778B 41.86
BrightSpring Health Services (BTSG) United States $3.070B 65.30
Ardent Health Partners (ARDT) United States $2.577B 0.00
Alignment Healthcare (ALHC) United States $2.546B 0.00
Concentras Parent (CON) United States $2.480B 0.00
Premier (PINC) United States $2.271B 11.34
GoodRx Holdings (GDRX) United States $2.254B 84.86
GeneDx Holdings (WGS) United States $2.057B 0.00
Ryman Healthcare (RYHTY) New Zealand $2.036B 0.00
Teladoc Health (TDOC) United States $1.575B 0.00
AMN Healthcare Services Inc (AMN) United States $1.507B 7.57
Progyny (PGNY) United States $1.425B 25.06
Establishment Labs Holdings (ESTA) $1.338B 0.00
Pediatrix Medical (MD) United States $1.319B 12.91
CareDx (CDNA) United States $1.228B 0.00
Agilon Health (AGL) United States $1.123B 0.00
Embecta (EMBC) United States $0.864B 5.76
InnovAge Holding (INNV) United States $0.822B 0.00
QDM (QDMI) Hong Kong, SAR China $0.790B 20.69
SBC Medicals (SBC) United States $0.722B 0.00
Auna S.A (AUNA) Luxembourg $0.488B 0.00
Sonida Senior Living (SNDA) United States $0.483B 0.00
Enhabit (EHAB) United States $0.382B 33.04
DocGo (DCGO) United States $0.355B 13.35
COMPASS Pathways (CMPS) United Kingdom $0.309B 0.00
Sera Prognostics (SERA) United States $0.255B 0.00
ModivCare (MODV) United States $0.232B 7.37
Beauty Health (SKIN) United States $0.211B 0.00
Biodesix (BDSX) United States $0.195B 0.00
LifeMD (LFMD) United States $0.192B 0.00
Ascend Wellness Holdings (AAWH) United States $0.178B 0.00
MultiPlan (MPLN) United States $0.136B 0.00
Nutex Health (NUTX) United States $0.127B 0.00
So-Young (SY) China $0.092B 22.35
Harvard Apparatus Regenerative Technology (HRGN) United States $0.059B 0.00
Singular Genomics Systems (OMIC) United States $0.057B 0.00
OncoCyte (OCX) United States $0.049B 0.00
NeueHealth (NEUE) United States $0.041B 1.63
Co-Diagnostics (CODX) United States $0.039B 0.00
IceCure Medical (ICCM) Israel $0.036B 0.00
NeuroOne Medical Technologies (NMTC) United States $0.027B 0.00
Pheton Holdings (PTHL) China $0.027B 0.00
Oncology Institute (TOI) United States $0.021B 0.00
SeaStar Medical Holding (ICU) United States $0.012B 0.00
XWELL (XWEL) United States $0.009B 0.00
Intelligent Bio Solutions (INBS) United States $0.007B 0.00
BioNexus Gene Lab (BGLC) $0.007B 0.00
KindlyMD (KDLY) United States $0.005B 0.00
ISpecimen (ISPC) United States $0.004B 0.00
NewGenIvf Group (NIVF) Thailand $0.003B 0.00
Aclarion (ACON) United States $0.002B 0.00
Cano Health (CANOQ) United States $0.001B 0.00